AI Proteins Secures $41.5M Series A Financing to Advance De Novo Microprotein Therapeutics Platform

Recently, AI Proteins, Inc.Al ProteinsAnnouncement Completed$41.5 Million Series AFinancing.

AI AI Proteins was founded in 2021,Headquartered inUnited StatesBostonTheSeedCompany，ByChris Bahl、Marc CohenAndCarl NovinaEstablishment。

Founder and CEO of the CompanyChristopher Bahl is a computational protein scientist, biochemist, and structural biologist.

During his time as a postdoctoral researcher in David Baker's lab at the Institute for Protein Design at the University of Washington, Chris pioneered the ability to computationally design miniature proteins from scratch.

The capability of AI Proteins lies in its ability to design microproteins that meet drug-specific characteristics.

Microprotein DrugsAre a class of compounds composed of less than or equal to 40 amino acids, sized between traditional small-molecule chemical drugs and large biologic drugs (such as antibodies), able to bind more effectively to targets,Penetrate tissues to reach the interior of tumors or solid tumors, etc.

AndAI Proteins PlatformCombined with technologies such as artificial intelligence, synthetic biology, and laboratory automation，Capable of rapidly designing and optimizing novel microproteins with ideal drug-like properties.

December 2024, AIProteins andBristol-Myers SquibbReach a value of$400 millionCooperation. UtilizeAI Proteins' AI-driven platform discovers and develops therapeutic microproteins targeting two undisclosed sites.

This round of financing, apart from continuing to promote the platform and pipeline, AIAI Proteins will also attempt to adopt a hub-and-spoke approach.（Hub）TheBusiness Model: While advancing its pipeline, it will continue to invest in its platform and begin spinning off assets into separate limited liability companies.

—END—

Recommended Reading